Ocugen on Twitter:
FDA slaps another hold on Ocugen, Bharat's COVID vaccine after WHO flags manufacturing problems | Fierce Pharma
Can COVID Vaccine Latecomer Ocugen Beat Pfizer and Moderna? | The Motley Fool
The Case For Covaxin: Ocugen CEO Shankar Musunuri :: In Vivo
ocgn-20210105xex991
Bharat Biotech, Ocugen to co-develop Covid-19 vaccine candidate
Stocks making the biggest moves in the premarket: Lordstown Motors, Ocugen, PepsiCo and more
Global Business Reports - Shankar Musunuri
2 Green Flags for Ocugen's Future | The Motley Fool
Ocugen seeks to sell 100 mln Indian vaccine doses in U.S. in 2021 | Reuters
ocgn-20200603xex991
Ocugen CEO discusses on distributing Covid-19 vaccines to U.S.
Ocugen expects $53.5M from stock sale amid efforts to bring Covaxin to the U.S. - Philadelphia Business Journal
Ocugen: WHO Approval For Covaxin Is A Red Herring For Investors (NASDAQ:OCGN) | Seeking Alpha
Ocugen Signs Letter of Intent to Acquire Liminal BioSciences | citybiz
ocgn-20220311.htm
Bharat Biotech's US partner Ocugen filed with US FDA for clinical trial of Covaxin - BusinessToday
Ocugen COVID shot will have to wait for US market as FDA slaps clinical hold on phase 3 trial | Fierce Biotech
The Troubles Of Bharat Biotech's Us Partner Is Bad News For India's Pharma Industry | Mint
4 Numbers That Make Ocugen an Extremely Risky Buy | The Motley Fool
Ocugen gets a black eye as FDA denies emergency OK for COVID jab -
Ocugen commences rolling submission of COVAXIN to Health Canada
Covid-19: Ocugen says Covaxin under 'active review' in Canada | Latest News India - Hindustan Times
ocgn-20210105xex991| Full Name: | |
| Title: | |
| Description: | |
| Rating Value: | |
| Time: | |
| 2026-03-01 18:12:32 | |